Jan 1, 2024, 04:39
Talha Badar: Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL here
Talha Badar, Hematologist/Oncologist at Mayo Clinic Comprehensive Cancer Center, posted on X/Twitter:
“Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL here. With median fu of 53 mo DFS and OS are 75.8% and 80.7%! IKZF1 plus and emergence of T315I suggestive of inferior outcome.”
Source: Talha Badar/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12